172 related articles for article (PubMed ID: 24338276)
1. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.
Huang YQ; Han ZD; Liang YX; Lin ZY; Ling XH; Fu X; Cai C; Bi XC; Dai QS; Chen JH; He HC; Chen YR; Jiang FN; Zhong WD
Med Oncol; 2014 Jan; 31(1):820. PubMed ID: 24338276
[TBL] [Abstract][Full Text] [Related]
2. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
Zhou L; Xia D; Zhu J; Chen Y; Chen G; Mo R; Zeng Y; Dai Q; He H; Liang Y; Jiang F; Zhong W
Clin Transl Oncol; 2014 Oct; 16(10):906-13. PubMed ID: 24659377
[TBL] [Abstract][Full Text] [Related]
6. Expression of SOCSs in human prostate cancer and their association in prognosis.
Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
[TBL] [Abstract][Full Text] [Related]
7. Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer.
Luo HW; Chen QB; Wan YP; Chen GX; Zhuo YJ; Cai ZD; Luo Z; Han ZD; Liang YX; Zhong WD
Biomed Pharmacother; 2016 Mar; 78():116-120. PubMed ID: 26898432
[TBL] [Abstract][Full Text] [Related]
8. Decreased Expression of MYPT1 Contributes to Tumor Angiogenesis and Poor Patient Prognosis in Human Prostate Cancer.
Liang Y; Zhuo Y; Lin Z; Jiang F; Dai Q; Lu J; Dong W; Zhu X; Han Z; Zhong W
Curr Mol Med; 2018; 18(2):100-108. PubMed ID: 29974831
[TBL] [Abstract][Full Text] [Related]
9. SOXs in human prostate cancer: implication as progression and prognosis factors.
Zhong WD; Qin GQ; Dai QS; Han ZD; Chen SM; Ling XH; Fu X; Cai C; Chen JH; Chen XB; Lin ZY; Deng YH; Wu SL; He HC; Wu CL
BMC Cancer; 2012 Jun; 12():248. PubMed ID: 22703285
[TBL] [Abstract][Full Text] [Related]
10. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.
Ling XH; Han ZD; Xia D; He HC; Jiang FN; Lin ZY; Fu X; Deng YH; Dai QS; Cai C; Chen JH; Liang YX; Zhong WD; Wu CL
Mol Biol Rep; 2014 May; 41(5):2779-88. PubMed ID: 24452717
[TBL] [Abstract][Full Text] [Related]
12. High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer.
Deng Y; Liu L; Feng W; Lin Z; Ning Y; Luo X
Recent Pat Anticancer Drug Discov; 2021; 16(4):533-539. PubMed ID: 34551701
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of matrix metalloprotease-1/protease-activated receptor-1 axis in patients with prostate cancer.
Wang J; Liu D; Zhou W; Wang M; Xia W; Tang Q
Med Oncol; 2014 Jun; 31(6):968. PubMed ID: 24805876
[TBL] [Abstract][Full Text] [Related]
14.
Cai C; Luo J; Liu Q; Liu Z; Zhao Y; Wu X; Yuegao Y; Lei Y; Lu J; Wang Y; Cai Z; Duan X; Lei M; Gu D; Liu Y
Genet Test Mol Biomarkers; 2021 Feb; 25(2):131-139. PubMed ID: 33596143
[No Abstract] [Full Text] [Related]
15. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.
Lin ZY; Huang YQ; Zhang YQ; Han ZD; He HC; Ling XH; Fu X; Dai QS; Cai C; Chen JH; Liang YX; Jiang FN; Zhong WD; Wang F; Wu CL
Int J Cancer; 2014 Aug; 135(3):541-50. PubMed ID: 24382668
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.
Wan Y; Zeng ZC; Xi M; Wan S; Hua W; Liu YL; Zhou YL; Luo HW; Jiang FN; Zhong WD
Hum Pathol; 2015 Feb; 46(2):295-303. PubMed ID: 25532941
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
19. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
